Cardiol Therapeutics (CRDL) Enterprise Value (2020 - 2026)

Cardiol Therapeutics has reported Enterprise Value for 7 years, with the latest figure at -$20.2 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 5.31% year-over-year to -$20.2 million; the trailing twelve-month figure through Mar 2026 stood at -$20.2 million (up 5.31% YoY), and the FY2025 full-year result was -$15.4 million, up 29.84% from the prior year.
• Enterprise Value for Q1 2026 stood at -$20.2 million, down from -$15.4 million in the prior quarter.
• The five-year high for Enterprise Value was -$13.1 million in Q2 2025, with the low at -$66.2 million in Q1 2022.
• Historically, Enterprise Value has averaged -$34.7 million across 5 years, with a median of -$25.7 million in 2023.
• Annual changes were most pronounced in 2022 — Enterprise Value slumped 497.73% — and 2025, when it soared 48.58%.
• Cardiol Therapeutics' Enterprise Value stood at -$43.8 million in 2022, then soared by 41.43% to -$25.7 million in 2023, then gained by 14.68% to -$21.9 million in 2024, then gained by 29.84% to -$15.4 million in 2025, then tumbled by 31.4% to -$20.2 million in 2026.
• The last three Enterprise Value figures came in at -$20.2 million (Q1 2026), -$15.4 million (Q4 2025), and -$22.2 million (Q3 2025), per Business Quant data.